<DOC>
	<DOCNO>NCT02636088</DOCNO>
	<brief_summary>In patient esophageal cancer , treatment curative intent give medically fit patient without distant metastasis . It may consist chemoradiotherapy surgery alone combination . Surgery combination chemotherapy another option . For patient medically fit surgery unresectable invasion adjacent structure alternative curative intent , current knowledge , definitive chemoradiotherapy . In current study investigator aim improve prognosis patient suitable surgery . Patients receive treatment conventional chemoradiotherapy ( oxaliplatin , fluorouracil radiotherapy ) addition recently develop drug , antibody call cetuximab .</brief_summary>
	<brief_title>Definitive Chemoradiotherapy Cetuximab Treatment Locally Advanced Esophageal Cancer</brief_title>
	<detailed_description>Patients treat three cycle oxaliplatin fluorouracil 750 mg/m2/24 hour , day 1-5 . Each cycle last 21 day . Oxaliplatin give 130 mg/m2 first cycle cycle 2 3 administer concomitant radiotherapy dose reduce 85 mg/m2 . A load dose cetuximab 400 mg/m2 give one week start radiotherapy , thereafter 250 mg/m2 give weekly course radiotherapy . Concomitant chemotherapy radiotherapy total dose 50 Gy give ( 2 Gy daily 25 fraction , 5 day week ) photon beam linear accelerator . After treatment patient follow every 6 month three year clinical examination CT-scan .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histological verify squamos cell carcinoma adenocarcinoma oesophagus cardia Performance status WHO 02 , age 1875 year Locally advance disease , nonresectable ( T4 N0N3 M0 ) disease operable reason ( T2/T3 N0N3 M0 ) Adequate hematological , liver renal function Written inform consent Distant metastases Prior chemotherapy radiotherapy oesophageal cancer cancer cardia Symptomatic peripheral neuropathy equal great NCI grade 2 Other concomitant serious illness medical condition would permit patient complete study treatment sign inform consent Myocardial infarction within 6 month prior study entry Second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin ) unless treat , remission active treatment great 2 year Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Phase II study , clinical trial</keyword>
</DOC>